Osmotica Pharmaceuticals plc logo
Osmotica Pharmaceuticals plc OSMT

Osmotica Pharmaceuticals plc Market Cap 2011-2026 | OSMT

As of April 06, 2026 Osmotica Pharmaceuticals plc has a market cap of $ 89.9 M


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Osmotica Pharmaceuticals plc

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
262 M 355 M 361 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
361 M 262 M 326 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
315 M - 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
127 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
33.6 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
168 B - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
549 M - -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
79 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
28.9 M - -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
76.4 M - - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
1.87 M - -9.65 % $ 45.9 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
22.1 M - - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
41.4 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
14.1 K - -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
19.6 M - 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
724 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
32.8 M - - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
3.25 B - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
172 M - 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
2.83 B - - - russiaRussia
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
71.4 M - 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
269 M - - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
38.2 M - 10.36 % $ 9.8 M usaUSA
Aravive Aravive
ARAV
60.4 M - -13.39 % $ 1.45 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
2.32 M - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
9.48 M - -39.0 % $ 4.57 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
3.53 B - - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
81.2 B - - $ 96.9 B britainBritain
Avenue Therapeutics Avenue Therapeutics
ATXI
544 K - -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
56.3 M - 1083.1 % $ 745 M usaUSA
Axcella Health Axcella Health
AXLA
25 M - -16.42 % $ 249 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.72 M - - $ 7.46 M israelIsrael
BeiGene, Ltd. BeiGene, Ltd.
BGNE
253 B - 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
67 M - - $ 546 M usaUSA
Allakos Allakos
ALLK
114 M - - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
11.4 M - -5.38 % $ 6.06 M usaUSA
Atreca Atreca
BCEL
49 M - -11.76 % $ 5.79 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
1.09 B - - $ 35.4 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
664 K - -11.43 % $ 502 K usaUSA
ChemoCentryx ChemoCentryx
CCXI
1.82 M - - $ 3.74 B usaUSA
AlloVir AlloVir
ALVR
13.1 M - 4.14 % $ 49.1 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
661 M - - - russiaRussia
Фармсинтез Фармсинтез
LIFE
2 B - - - russiaRussia
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
78.6 M - -74.18 % $ 955 K usaUSA
Chimerix Chimerix
CMRX
104 M - - $ 756 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
5.03 M - -13.85 % $ 16.1 M usaUSA
AbbVie AbbVie
ABBV
400 B $ 208.7 -0.07 % $ 369 B usaUSA
Calithera Biosciences Calithera Biosciences
CALA
960 M - -10.95 % $ 876 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
54.1 M - -3.03 % $ 260 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
427 M - - $ 2.91 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
962 M $ 3.52 -0.14 % $ 1.05 B canadaCanada